**SUPPORTING STATEMENT**

**Authorization Request Forms/Certification/Letter of Medical Necessity**

**Opioid Medications/Compounded Drugs**

**1240-xxxx**

**A. Justification:**

**1**. **Explain the circumstances that make the collection of information necessary. Identify any legal or administrative requirements that necessitate the collections. Attach a copy of the appropriate section of each statute and of each regulation mandating or authorizing the collection of information.**

**Background**

On March 23, 2016, the President of the United States, Barack Obama, responding to the escalation of prescription opioid abuse and the heroin epidemic, announced several actions taken by his Administration to address the epidemic, including steps to expand access for treatment, prevent overdose deaths and increase community prevention strategies.

The President had previously announced in October 2015 that several initiatives would be undertaken by the federal government as it related to opioid abuse and the heroin epidemic, noting that the Centers for Disease Control and Prevention (CDC) reported that overdose deaths involving prescription opioids quadrupled between 1999 and 2013, with more than 16,000 deaths in 2013. The CDC has identified addiction to prescription pain medication as the strongest risk factor for heroin addiction.

Additionally, the President in 2013 signed a law which provides greater federal oversight over compounding pharmacies that custom mix medication in bulk for patients who may benefit from prescriptions that are specific to their individual medical needs. *See* Compounding Quality Act, Pub. L. No. 113-54, 127 Stat. 587 (2013). Compounded medications (which may contain opioids) have two or more ingredients and are offered as an alternative to FDA-approved medications that do not meet an individual patient’s health needs, such as when a patient has an allergy that requires a medication to be made without a certain dye. *See* *Compounding and the FDA: Questions and Answers*, FDA, <http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm339764.htm>.

Compounded drugs are not FDA-approved. This means that the FDA does not verify the safety or effectiveness of compounded drugs. Consumers and health professionals rely on the drug approval process to ensure that drugs are safe and effective and made in accordance with Federal quality standards. Compounded drugs also lack an FDA finding of manufacturing quality before such drugs are marketed.

Health risks associated with compounded drugs include the use of ingredients that may be sub- or super‑potent, contaminated, or otherwise adulterated. Additionally, patients may use ineffective compounded drugs instead of FDA-approved drugs that have been shown to be safe and effective.

**Impacts on the FECA Program**

The Federal Employees’ Compensation Act (FECA), 5 U.S.C. 8101 et seq., provides compensation benefits to Federal employees for work-related injury/illness and to their surviving dependents if a work-related injury/illness results in the employee’s death. Section § 8145 provides the Secretary of Labor the authority to delegate the responsibility to administer the FECA program to OWCP; through this delegation OWCP has the authority and the responsibility to decide all questions arising under the FECA. 5 U.S.C. § 8145.

Section 8103 provides:

The United States shall furnish to an employee who is injured while in the performance of duty, the services, appliances, and supplies prescribed or recommended by a qualified physician, which the Secretary of Labor considers likely to cure, give relief, reduce the degree or the period of disability, or aid in lessening he amount of the monthly compensation. 5 U.S.C. § 8103.

A number of injured workers receiving benefits under the FECA program are prescribed opioid medication. While most prescriptions are short term in nature, some patients remain on these habit-forming medications for a long period of time.

In recent years, the FECA program has seen an exponential increase in the number of compounded drug prescriptions being submitted for payment in workers’ compensation claims. A greater number of claimants are receiving these medications and are receiving them more frequently, increasing concern about the efficacy and safety of these prescriptions for our injured federal workers.

Statutorily, FECA is mandated to provide medically necessary supplies and services to treat work related injuries. However, the FECA statute gives broad discretionary authority to determine the medical necessity of supplies and services used to treat work related injuries. Because of the increase in compounded drugs and safety concerns for both compounded drugs and opioids, the Department of Labor has deemed it necessary to more closely review the medical necessity of these medications in FECA claims by instituting a pre-authorization process.

Due to concerns about the safety, efficacy, and medical necessity of these medications, we believe that the two new forms that OWCP is introducing with this OMB clearance request will provide a vehicle for more closely monitoring their use. These forms will further strengthen medical management procedures for prescription drugs, assist our stakeholders in controlling costs from medically unnecessary treatments, and lessen the impact of potential drug addiction and medical fraud.

These major health care issues have also encroached upon the OWCP with escalation in program costs and with the use of compounded medications within the federal agencies OWCP services. For example, for the United States Postal Service, the total number of claims involving compounded medication has doubled – from 6,747 in 2010 to 13,151, for the first six months of 2015. Associated costs have increased significantly, from $9 million in fiscal year 2013 to $99 million in fiscal year 2015. The Department of Veterans Affairs reports spending $5.6 million on compounded medications in fiscal year 2014; in fiscal year 2010, the amount was only $22,000.

A major goal of the FECA program is to return an injured employee back to employment as soon as medically feasible. The forms that are being proposed will serve as a means for injured workers to continue receiving opioids and compounded drugs only where medically necessary and simultaneously give OWCP greater oversight in monitoring their use. Requiring Prior Authorization will assist OWCP in determining whether the prescribed medication will assist in curing, giving relief, and lessening the degree of disability. FECA further provides OWCP the authority to conduct such investigation as necessary before making an award of compensation (including the need for medical treatment by certain prescription drugs). 5 U.S.C. § 8124(a)(2). Finally 5 U.S.C. § 8149 provides OWCP the authority to prescribe rules and regulations necessary for the administration of FECA. We note that the Department has issued regulations relating to its authority to require prior authorization for medical treatment which will now be applied through these forms to compounded drugs and opioids. (20 CFR 10.310, 10.800 & 10. 809).

<https://www.dol.gov/owcp/dfec/regs/statutes/feca.htm>

<http://www.ecfr.gov/cgi-bin/text-idx?c=ecfr&SID=c131552afa82be329e42e2c9d62a41c8&rgn=div5&view=text&node=20:1.0.1.2.2&idno=20>

As such, OWCP proposes the following two forms to fulfill these requirements and obligations under the FECA.

1. CA- 26. Authorization Request form and Certification/Letter of Medical Necessity for Compounded Drugs.

2. CA- 27. Authorization Request form and Certification/Letter of Medical Necessity or Opioid Medications.

**2**. **Indicate how, by whom, and for what purpose the information is to be used. Except for a new collection, indicate the actual use the agency has made of the information received from the current collection.**

The CA-26 and the CA-27 are similar in nature, and are required to be certified by a claimant’s treating physician. The treating physician will be required to indicate all ingredients that are being prescribed, whether the medication and the ingredients, as applicable, are medically necessary or not (with consideration of non-opioid and non-compounded drugs as alternative dispensing methods). The physician must also consider cost effectiveness as part of his or her authorization/certification request for compounded drugs. These forms will be required to be on file each time the treating physician prescribes such medications, and will be maintained in a database held by our medical billing services contractor and passed along to DOL Claims Examiners when their review is required. In order to complete and submit this information, the treating physician must be enrolled and registered with our medical services contractor provider (which is accomplished via an OMB approved form).

The forms themselves will permit OWCP to more easily track the volume, type, and characteristics of opioids and compounded drugs used in the FECA program. As noted, these forms require the certification/signature of the treating physician and will be maintained by medical billing services contractor. An electronic signature will be pursued in a later clearance under a non-material change. In the interim, the physician will have signed the original OMB-approved provider registration form and these new forms will incorporate that signature by reference. Failure to complete the required documentation could result in delayed payments/prescriptions or an unfavorable decision or reduced level of benefits.

OWCP has a contracted vendor to provide medical bill processing services for their benefit programs. This program reimburses medical and non-medical providers for their services rendered for the use and treatment of a claimant’s compensable condition.

**3**. **Describe whether, and to what extent, the collection of information involves the use of automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g. permitting electronic submission of responses, and the basis for the decision for adopting this means of collection. Also describe any consideration of using information technology to reduce burden.**

While OWCP will disseminate information on its Website concerning these forms, the form itself will not be accessible on a public domain website, but found on our contracted medical vendor’s website. In order to access the form, the treating physician will need to be registered with our program. The treating physician will have the ability to electronically submit the form to our contracted medical vendor. The electronic version is in the same format as the paper form. The Department will ask for a non-substantive change in the very near future as the electronic version of the form and the screen shots related to the electronic version of these form are finalized.

**4**. **Describe efforts to identify duplication. Show specifically why any similar information already available cannot be used or modified for use for the purposes described in Item A.2 above.**

There is no similar information available.

**5**. **If the collection information impacts small businesses or other small entities, describe any methods used to minimize burden.**

This information collection has been streamlined to obtain the necessary information while imposing the minimum burden on the respondent. This information collection does not have a significant economic impact on a substantial number of small entities.

As previously addressed, these forms will eventually be electronically formatted, and transmitted with the use of electronic signature by the providers to our contracted medical provider. This enhancement will reduce the time and costs of mailing the documents.

**6**. **Describe the consequence of Federal program or policy activities if the collection is not conducted or is conducted less frequently, as well as any technical or legal obstacles to reducing burden.**

**Failure to impose a preauthorization process may result in increases in the use of compounded and opioid drugs, raising safety and cost concerns.**

**7**. **Explain any special circumstance required in the conduct of this information collection.**

There are no special circumstances for this information collection.

**8**. **If applicable, provide a copy and identify the date and page number of publication in the Federal Register of the agency's notice, required by 5 CFR 1320.8 (d), soliciting comments on the information collection prior to submission to OMB. Summarize public comments received in response to that notice and describe actions taken by the agency in response to these comments.**

A Federal Register Notice inviting public comment was published on June 22, 2016 (81 FR 40721). The agency received three comments via email. All commentators were in agreement with the proposal and provided their reasons for support, which also highlighted some of the concerns addressed by the Federal Employees’ Compensation program in this proposed collection. Summaries of the three comments are noted below.

Public Comment Number 1: The commenter wrote that the proposal was a great start in combating the drug epidemic and a means to fight medical fraud. In their email, it was also suggested that forms include a photo ID and an electronic signature. Furthermore, the commenter believed pharmacists should ask for a photo ID before dispensing/picking up prescriptions.

Public Comment Number 2: The commenter, a Professor of Medicine and Pharmacy, and a nationally recognized expert in drug safety and pharmacotherapy, cited a recent article from the Washington Post which addressed the soaring costs of compounded drugs reported by OWCP. He also addressed the associated risks, safety and efficacy issues with compounds, noting that preference should be given to FDA approved prescriptions. He added that the physician, when recommending the usage of compound drugs, should provide documentation in the Letter of Medical Necessity that includes high, quality published evidence in medical literature that supports safety and efficacy of the specific product(s).

Public Comment Number 3: The commenter, a Doctor of Pharmacy, expressed his support and advocacy of OWCP’s proposal. In his statement, he shared concerns regarding the increased dispensing of opioid medication and compounded drugs and their effect on abuse and addiction among the injured workers. He noted that prior authorization requests have been initiated in several states, such as Washington, Ohio, Texas, and Oklahoma, which have “led to improved treatment dialogues between prescriber and injured workers and reduced the use of inappropriate and habit forming medications”. He also noted that over the 20 years that a pharmacy company providing services to the nations’ injured workers has found that prior authorizations have been “amongst the single-most effective and meaningful in combating overuse and abuse of both opioids and compound medications.” In closing, the commenter expressed the view that adopting such forms will help to reduce the over-prescribing of “secondary (or tertiary) medication therapies and will result in a safe, healthier, and more empowered Federal injured worker population.”

OWCP Response: Overall, all three commenters agreed with OWCP’s proposal and highlighted similar concerns that we have noted related to increased cost, safety and efficacy issues, particularly with compounded drugs. The first commenter suggested that perhaps that the Letter of Medical Necessity include a photo ID or electronic signature. He further recommended thatpharmacists, before dispensing/pick up of medication ask for photo ID. With respect to the electronic signature and photo ID suggestion, OWCP believes the proposed processes are sufficient at this time. The requirement to present a Photo ID to verify the patient’s identity at the time a prescription is filled varies among states and pharmacies.  Instituting such a requirement is not within the scope and purview of this proposal which is aimed at obtaining the physician’s medical opinion on the necessity of the medication. In response to the second commenter’s recommendation, we have clarified the form that in addition to explaining their medical rationale for why the compounded drug is medically necessary for the particular patient and that that the physician may cite relevant medical literature to support his opinion concerning the need for the medication as well as the safety and efficacy of the specific products being recommended.

With respect to the third commenter, OWCP has no further response as the comments expressed a strong level of support for OWCP’s efforts to introduce a prior authorization process and did not include further recommendations. We do commend each of the commenters on their feedback and expressing their concerns about OWCP’s initiative for a prior authorization process.

**9**. **Explain any decision to provide any payment or gift to respondents, other than remuneration of contractors or grantees.**

No payments or gifts are made to respondents to furnish the information.

**10**. **Describe any assurance of confidentiality provided to respondents and the basis for the assurance in statute, regulations, or agency policy.**

The information collected by these requests is maintained in FECA claim files, which are fully protected under the Privacy Act. Records pertaining to compensation cases are covered under the Privacy Act. The Privacy Act Notice is provided on each of the forms. All forms used to initiate a compensation claim contain a statement advising the claimant of the provisions of the Privacy Act. The applicable Privacy Act system of records is called DOL/GOVT-1.

See web site: <http://www.dol.gov/sol/privacy/dol-govt-1.htm>

1. **Provide additional justification for any questions of a sensitive nature, such as sexual behavior and attitudes, religious beliefs, and other matters that are commonly considered private. This justification should include the reasons why the agency considers the questions necessary; the specific uses to be made of the information, the explanation to be given to persons from whom the information is requested, and any steps to be taken to obtain their consent.**

No questions of a sensitive nature concerning sexual preference, religion, etc. are requested. However, while questions regarding a patient’s diagnosis and prescribed medications may be considered, this information is covered under the Privacy Act System of Records. Specifically, this System may contain the following kinds of records: reports of injury by the employee and/or employing agency; claim forms filed by or on behalf of injured Federal employees or their survivors seeking benefits under FECA; forms authorizing medical care and treatment; other medical records and reports; bills and other payment records; compensation payment records; formal orders for or against the payment of benefits; transcripts of hearings conducted; and any other medical, employment, or personal information submitted or gathered in connection with the claim.

As previously addressed, requesting this information will assist OWCP in determining whether prescriptions are medically necessary for the treatment of the injury/occupational disease and that such prescriptions are being recommended for medical diagnosis(es) that the OWCP has accepted as being compensable under the Act.

**12**. **Provide estimates of the hour burden of the collection of information. The statement should:**

* **Indicate the number of respondents, frequency of response, annual hour burden, and an explanation of how the burden was estimated. Unless directed to do so, agencies should not make special surveys to obtain information on which to base burden estimates. Consultation with a sample of potential respondents is desirable. If the burden on respondents is expected to vary widely because of differences in activity, size, or complexity, show the range of estimated burden and explain the reason for the variance. Generally, estimates should not include burden hours for customary and usual business practices.**

Based on data provided by our contracted medical billing provider, we estimate the average number of responses/burden hours based on prescription data during the FY2013-FY2015.

|  |  |  |  |
| --- | --- | --- | --- |
| **Form** | **Time to Complete (min)** | **Number of Responses** | **Burden Hours** |
| **CA-26** | **30** | **15,500\*** | **7,750** |
| **CA-27** | **30** | **154,500\*** | **77,250\*\*** |
| **Total** |  | **170,000** | **85,000** |

**Calculation of burden hours**

**CA-26: 30 minutes X 15,500/60 = 7,750**

**CA-27: 30 minutes x 154,500/60 = 77,250**

**\* DOL assumes approximately 14,200 persons will respond to Form CA-26 and will each make an average of 1.1 submissions, for a total of 15,500 responses. DOL assumes approximately 37,500 persons will respond to Form CA-27 and will each make an average of 4.1 submissions, for a total of 154,500 responses.**

**\*\*DOL will pilot a review process in which the CA-27 is effective for 30 days, but may move to a process in which it is effective for 60 or 90 days. If DOL makes a change to lengthen the effective period from 30 to 60 or 90 days, the estimated reduction in burden annually is 21,000 hours (56,250 burden hours) and 42,000 hours (35,250 burden hours), respectively. We will submit such a change to OMB via a nonsubstantive change request, and will include the amended CA-27.**

The combined burden hours have been calculated to be 85,000. We have estimated the cost of the burden hours at $8,079,250) using the current mean hourly wage of ($95.05) reported for physicians and surgeons (based on Bureau of Labor Statistics data for May 2015)

Reference: <http://www.bls.gov/oes/current/oes291069.htm>

$95.05 x 85,000 = $8,079,250.

1. **Annual Costs to Respondents (capital/start-up & operation and maintenance).**

As these forms will be ultimately electronically submitted to our medical services vendor, the respondents will incur no operation or maintenance costs.

**14**. **Provide estimates of annualized cost to the Federal government.**

**Process/Review Costs**:

-- By OWCP staff: The average hourly wage for the Claims Examiner is a GS 12/6 at $39.70 per hour.

Reference: <https://www.opm.gov/policy-data-oversight/pay-leave/salaries-wages/salary-tables/pdf/2016/RUS_h.pd>

It is estimated that Claims Examiners will need to review approximately 5% of the CA-26 forms, which will take an average of 12.5 hours to process. It is estimated that Claims Examiners will need to review all CA-27 forms, which will take an average of 2.5 hours to process.

|  |  |  |  |
| --- | --- | --- | --- |
| **Form** | **Time to Process/Review** | **Number of Responses** | **Costs** |
| **CA-26** | **12.5 hours** | **\* 775** | **$384,594** |
| **CA-27** | **2.5 hours** | **154,500** | **$15,334,125** |
| **Total** |  | **155,275** | **$15,718,719** |

\*CA-26 15,500 x .05 = 775

-- By Contracted Medical Services Vendor: Under OWCP’s contractor medical bill processing system, necessary modifications to review and process CA-26 and CA-27 forms will be $2,100,000. In addition, the contractor cost to process one form is $3.44 for a total cost of $534,146 (155,275 x $3.44).

**Federal Cost Estimates:**

**Printing costs**: There is no printing cost associated with either of these forms since both forms will only be stored on our contracted medical services website.When needed, updates are issued in the form of bulletins to the programs’ provider community. Printing and mailing costs for provider notices and bulletins are built into the contract that OWCP has with the contracted medical services vendor.

**Mailing and Envelope Cost:**  We anticipate that there are no mail costs involved as these forms will be available for electronic completion and submission via our contracted medical services vendor.

**Total Federal Cost**: $17,818,719 (OWCP/Contracted Medical Vendor = $15,718,719 + $2,100,000)

**15**. **Explain the reasons for any program changes or adjustments.**

This is a new collection request. There are no program changes or adjustments in Items 13 or 14.

**16**. **For collections of information whose results will be published, outline plans for tabulation and publication. Address any complex analytical techniques that will be used. Provide the time schedule for the entire project, including beginning and ending dates of the collection information, completion of report, publication dates, and other actions.**

There are no plans to publish this collection of information.

**17**. **If seeking approval to not display the expiration date for OMB approval of the information collection, explain the reasons that display would be inappropriate.**

This ICR does not seek a waiver from the requirement to display the expiration date.

**18**. **Explain each exception to the certification statement identified in ROCIS.**

There are no exceptions to the certification statement.

**B. Collections of Information Employing Statistical Methods**

Statistical methods are not used in these collections of information.